Your Health, We Care
Most common adverse reactions (≥ 40%) are: vomiting, rash (all), abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain, pyrexia, acneiform rash, stomatitis, headache, paronychia, and pruritus.
from FDA，2024.01
By targeting and inhibiting the activity of MEK protein, Koselugo effectively cu···【more】
Release date：2024-08-23Recommended：271
Koselugoinhibits tumor cell proliferation by inhibiting MEK protein activity, bl···【more】
Release date：2024-08-23Recommended：230
Koselugo is a targeted therapy drug primarily used to treat a specific subtype o···【more】
Release date：2024-08-23Recommended：263
